Open AccessIncrease of the Ventricular Fibrillation Threshold by 711389-S, a New Antiarrhythmic Agent, in Guinea-Pigs
Author(s) -
Shōichi Nakajima,
Motohiko Ueda
Publication year - 1985
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.38.436
Subject(s) - quinidine , disopyramide , lidocaine , propranolol , ventricular fibrillation , in vivo , antiarrhythmic agent , pharmacology , guinea pig , anti arrhythmia agents , medicine , cardiology , anesthesia , atrial fibrillation , biology , heart disease , microbiology and biotechnology
The increase of the ventricular fibrillation threshold (VFT) by 711389-S, a new antiarrhythmic agent, was compared with several other antiarrhythmic drugs using both in vitro (Langendorff) and in vivo preparations of guinea-pigs. The doses of antiarrhythmic drugs for increasing VFT by 10 volts in in vitro (microgram) and in vivo (mg/kg, i.v.) preparations were as follows: 711389-S: 4.2, 0.15; disopyramide: 32.6, 0.86; quinidine: 32.0, 0.57; aprindine: 7.6, 0.55; propranolol: 16.6, 0.57; and lidocaine: 20.7, 1.52. The duration of the antifibrillatory effects of 711389-S almost corresponded with those of aprindine and propranolol.